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INTRODUCTION
Although the overall incidence of lung cancer has decreased by 0.8% annually from 1999 to 2005, it remains the leading cause of death by malignant tumors worldwide (1) . Adenocarcinoma, the most prevalent histology, is present in 50% of non-small cell lung cancer (NSCLC) (2) . Most lung adenocarcinoma-associated somatic epidermal growth factor receptor (EGFR) tyrosine kinase mutations were in-frame deletions in exon 19 and a point mutation (leucine to arginine [L858R]) in exon 21 (3).
Patients whose tumors contain either of these mutations exhibit increased sensitivity to tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib (4) .
One of the important signaling mediators downstream in human cancers is signal transducer and activator of transcription 3 (STAT3). STAT3 is also persistently activated in ~50% of NSCLC primary tumors and lung cancer-derived cell lines (5) . STAT3 is activated by phosphorylation of Tyr705, leading to dimerization, nuclear translocation, DNA binding, and gene activation (6) . STAT3 activation by cytokines is mediated through the Janus family kinases (JAK) or SRC (7) . JAKs include four family members: JAK1, JAK2, JAK3, and TYK2. JAK1, JAK2, and TYK2 are expressed ubiquitously, whereas expression of JAK3 is primarily restricted to the lymphoid lineage (8) . JAK1/2 inhibitors such as AZD1480 suppressed activation of STAT3 and showed anticancer effects using human cancer cell lines and xenograft tumors, including lung cancer (9) . However, the effect of JAK1/2 inhibitors on NSCLC harboring an EGFR mutation remains unclear.
We established transgenic mice expressing the delE748-A752 mutant of mouse Egfr, which corresponded to the delE746-A750 mutant of human EGFR (10) . In the transgenic mice, pSTAT3 was overexpressed in the bronchioloalveolar carcinoma component around the adenocarcinoma center (11) . In the present study, the efficacy of AZD1480 was evaluated using EGFR mutant cell lines, xenograft mice, and transgenic mice.
MATERIALS AND METHODS

Reagents
Gefitinib and AZD1480, a 4-(pyrazol-3-ylamino) pyrimidine derivative, were kindly provided by AstraZeneca and dissolved in dimethyl sulfoxide (DMSO) for in vitro studies. AZD1480 was suspended in water supplemented with 0.5% hypromellose and 0.1% Tween 80 for in vivo experiments. Rabbit antisera against EGFR, phospho-specific EGFR (pEGFR; pY1068), phospho-specific STAT3 (pSTAT3; Tyr705), phospho-specific JAK1 (pJAK1; Tyr1022/1023), phospho-specific JAK2 (pJAK2; Tyr1007/1008), mitogen-activated protein kinase (MAPK), phospho-specific MAPK (p-MAPK; pT202/pY204), AKT, phospho-specific AKT (pAKT; pSer473), cleaved PARP, cleaved caspase-3 (Asp175; 5A1E), and GAPDH were purchased from Cell Signaling Technology (Beverly, MA). Antibodies against STAT3, JAK1, and JAK2 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Rat antisera against CD31 (PECAM-1) were purchased from Dianova (Hamburg, Germany).
Cell Lines
HEK293T cells were cultured at 37.0°C with 5% CO 2 by using Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum, 1% minimum essential medium, nonessential amino acid solution, and 2 mM L-glutamine. PC-9 is a lung adenocarcinoma cell line that has an in-frame deletion mutation at exon 19 of EGFR. PC-9 and H1975 were purchased from Immuno-Biological Laboratories (Takasaki, Gunma, Japan) and the American Type Culture Collection (Manassas, VA), respectively. A gefitinib-resistant cell line (RPC-9), a vandetanib-resistant cell line (PC-9/Van-R), and an erlotinib-resistant cell line (PC-9/ER3) were established from a parental PC-9 cell line in our laboratory (12) (13) (14) . RPC-9 and PC-9/VanR cells were 400-and 138-fold more resistant to gefitinib than PC-9 cells, respectively. PC-9/ER3 cells were 136-fold more resistant than the parental cells to erlotinib. The resistance mechanism of RPC-9 and PC-9/Van-R was due mainly to a secondary mutation of T790M and that of PC-9/ER3 was due to JAK2 activation (12) (13) (14) . These cell lines were cultured in RPMI-1640, 10% fetal bovine serum, and 1% penicillin/streptomycin in a tissue culture incubator at 37°C under 5% CO 2 .
Transfection of EGFR
The EGFR expression vectors were constructed by inserting the full-length reverse transcription-polymerase chain reaction (RT-PCR) product of human EGFR into the pcDNA3.1-Zeo vector (Invitrogen, Carlsbad, CA). The deletion mutation was generated by site-directed mutagenesis using a QuikChange kit (Stratagene, La Jolla, CA). The mutation was confirmed by sequencing. The EGFR expression vector was kindly provided by Professor Takata (Radiation Biology Center, Kyoto University) and was introduced into HEK293T cells using Fugene6 (Roche Applied Science, Basel, Switzerland).
Stable EGFR-expressing clones were isolated by limiting dilution.
Cell Viability Assay
Growth inhibition was measured using a modified 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (15) . Briefly, the cells were plated on 96-well plates at a density of 2,000 per well and continuously exposed to each drug for 96 h. Each assay was performed in triplicate or quadruplicate.
The drug concentration required to inhibit the growth of tumor cells by 50% (IC 50 ) was used to evaluate the sensitivity of gefitinib or AZD1480.
Immunoblotting
Cells were lysed in radioimmunoprecipitation assay buffer [1% Triton X-100, 0.1% SDS, 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10 mM -glycerol-phosphate, 10 mM NaF, 1 mM sodium orthovanadate] containing a protease inhibitor tablet (Roche Applied Sciences GmbH, Basel, Switzerland). Mouse lung tissues were frozen in liquid nitrogen, crushed by applying pulsed pressure, and lysed in RIPA buffer. Each protein was separated by electrophoresis on polyacrylamide gels, transferred onto nitrocellulose membranes, and probed with specific antibodies followed by detection with enhanced chemiluminescence plus reagents (GE Healthcare Biosciences, Tokyo, Japan).
Xenograft Model
Female athymic mice at 7 weeks of age were purchased from Japan Charles River Co. (Kanagawa, Japan). 
Transgenic Mouse Model
We generated transgenic mice expressing the delE748-A752 mutant of mouse Egfr, which is equivalent to the delE746-A750 mutant (10) . The transgenic mice used the SP-C promoter to express mutated Egfr in type II alveolar cells. In the absence of gefitinib treatment, the transgenic mice developed adenocarcinoma at 6 to 7 weeks of age and died due to tumor progression at 13 to 18 weeks (10). Transgenic mice were randomly assigned to five groups that received either vehicle alone or AZD1480 (1, 10, 30, or 50 mg/kg/day) from 7 to 10 weeks of age. Vehicle and AZD1480 were administered once daily, six times per week by gavage. The number of superficial lung tumors (long axis exceeding 1 mm) in the left lung was counted at 10 weeks of age. To evaluate the effect of AZD1480 on survival in EGFR transgenic mice, the mice were treated with AZD1480 (30 mg/kg/day) or vehicle alone from 7 weeks of age until they died.
Immunohistochemistry
Formalin-fixed paraffin-embedded tissue blocks were cut to a thickness of 5 μm, placed on glass slides, and then deparaffinized in xylene and graded alcohol. The antigen was incubated in 10 mM sodium citrate buffer (pH 6.0) for 10 min in a 95°C water bath. The sections were then blocked for endogenous peroxidase with 0.3% hydrogen peroxide in methanol for 10 min. The slides were rinsed with Tris-buffered saline containing 0.1% Tween 20, and the sections were blocked with normal goat serum for 60 min. The sections were incubated with anti-pSTAT3 monoclonal antibody or anti-mouse CD31 antibody overnight at 4°C. The sections were amplified using biotinylated anti-rabbit (or anti-rat) antibodies and avidin-biotinylated horseradish peroxidase conjugate for 10 min (LSABTM 2 Kit; DakoCytomation, Glostrup, Denmark), and then reacted with 3,3-diaminobenzidine. Finally, the sections were counterstained with hematoxylin. CD31 blood vessels or pSTAT3 cells were counted in six random fields (×200). All immunohistochemical analyses were completed independently by two investigators (T.M. and N.T.).
Statistical Analysis
Statistical analysis was performed using the SPSS Base System™ and Advanced Statistics™ programs (SPSS, Chicago, IL). Group differences were compared using Student's t-test. Survival time was defined as the period from initiation of treatment to death. Overall survival curves were calculated using the Kaplan-Meier method. A p value less than 0.05 was deemed to indicate statistical significance.
RESULTS
Sensitivity to AZD1480 In Vitro
HEK293T cells transfected with the EGFR deletion mutant demonstrated increased expression of pJAK1, pJAK2, and pSTAT3, as well as pEGFR, than control cells (Fig. 1A) . Next, inhibition of STAT3 using AZD1480 was examined in EGFR-addicted lung cancer cells. Figure 1B 
Effects of AZD1480 on PC-9 Tumors in the Xenograft Model
The tumor volume receiving vehicle, 30 mg/kg/day AZD1480, or 50 mg/kg/day AZD1480 is shown in Fig.   2A . PC-9 tumors in both AZD1480-treated groups were significantly smaller than those in the vehicle-treated group (vehicle vs. 30 mg/kg/day AZD1480, p<0.05; vehicle vs. 50 mg/kg/day AZD1480, p<0.01; day 21). We next investigated the antiangiogenic effect of AZD1480 on PC-9 tumors. Following a week of treatment with AZD1480 (50 mg/kg/day), tumor specimens were immunostained for endothelial cell marker CD31 (Fig. 2B ). We found a marked reduction in CD31-positive tumor blood vessels in AZD1480-treated mice compared with control (p<0.0001, Fig. 2C ).
The Effect of AZD1480 on Activating EGFR-driven Lung Cancer
Pathologically, the EGFR transgenic mice did not harbor lung tumors at 1 week and 3 weeks; however, they developed adenocarcinoma at 7 weeks (Fig. 3A) . Not surprisingly, EGFR was activated even at 1 week. pSTAT3 expression was higher at 7 weeks than at 3 weeks. Figure 3B shows that gefitinib could inhibit pEGFR, but not pJAK1, pJAK2, or pSTAT3, and AZD1480 suppressed pJAK1, pJAK2, and pSTAT3. The numbers of lung tumors (long axis exceeding 1 mm) ± standard error in the AZD1480-treated groups (30 and 50 mg/kg) and control group were 0.38 ± 0.18, 0.13 ± 0.13, and 2.25 ± 0.53 (t-test, p<0.001), respectively (Fig. 3C ). The number of tumors observed with 1 and 10 mg/kg AZD1480 did not differ significantly from that in the control group. Pathological examination also revealed a marked reduction in tumors in the 30 and 50 mg/kg groups; however, tumors in the 1 and 10 mg/kg groups were comparable with that in the control group (Fig. 3D) .
Following these findings, AZD1480 (30 mg/kg) was administrated once to transgenic mice. The lungs were removed 2, 6, 12, or 16 h after treatment. The lung specimens were immunostained using pSTAT3 antibody (Fig. 4A) . The specimens collected at 2 and 6 h after AZD1480 administration showed decreased expression of pSTAT3, whereas the specimens collected at 12 and 16 h showed increased expression of pSTAT3 (Fig. 4B ). Subsequently, protein was extracted from each removed lung and was subjected to Western blotting. Suppression of pSTAT3 was noted at 2 and 6 h after AZD1480 administration and cleaved PARP and caspase 3 were also observed (Fig. 4C) .
To evaluate the effect of AZD1480 on survival in the EGFR transgenic mice, AZD1480 (30 mg/kg/day, n = 13) or vehicle (n = 13) was administered by gavage from 7 weeks of age. The AZD1480-treated group demonstrated a greater weight than that of the vehicle-treated group (p<0.001, 9
weeks) (Fig. 5A) . The median survival time in the AZD1480-treated group (217 days) was significantly greater than that in the control group (106 days) (log-rank test, p<0.0001, Fig. 5B ).
DISCUSSION
STAT3 has essential functions in both tumor cells and the tumor microenvironment to facilitate cancer progression. Multiple studies from independent groups have demonstrated evidence for STAT3 activation in nearly 50% of lung cancers (16) . We found that AZD1480, which targets the JAK/STAT3 signal pathway, was effective for lung tumors harboring an exon 19 deletion mutation.
STAT3 can be activated by EGFR, whereas it has been shown that activation of STAT3 by EGFR is indirect, and also acts through JAK kinase via IL-6 (9, 16, 17) . We previously showed that STAT3
was less suppressed compared with EGFR despite the administration of gefitinib to EGFR-transgenic mice: signals from other upstream factors might activate STAT3 even in EGFR-driven lung cancer (11) .
We also reported that increased pJAK2 expression was partially due to acquired erlotinib resistance (14) .
In the present study, inducing a deletion mutation of EGFR into HEK293T cells increased expression of pJAK1, pJAK2, and pSTAT3, as well as that of pEGFR (Fig. 1A) . Thus, we hypothesized that AZD1480
was effective in terms of targeting EGFR-mutated lung cancer and overcoming acquired resistance to EGFR-TKI.
AZD1480 showed IC 50 s of approximately 1-2 μM for PC-9, RPC-9, PC-9/VanR, and PC-9/ER3 cells. Thus, no cross-resistance between EGFR-TKI and AZD1480 was found. The different AZD1480 concentrations (0.001 and 0.1 μM) inhibiting pJAK1/JAK2 and pSTAT3, respectively (Fig. 1C) , suggest the existence of an upstream protein other than EGFR, JAK1, and JAK2. AZD1480 did not block tumor cell growth in vitro at levels that produced maximal inhibition of pSTAT3, although tumor growth was inhibited directly in vivo (9, 18) . We also confirmed that AZD1480 was effective in the xenograft model ( Fig. 2A) . Constitutive activation of STAT3 within tumor cells and stromal cells promotes cancer cell proliferation, invasion, angiogenesis, and immune evasion (19) . The effect of AZD1480 on the tumor microenvironment was recently demonstrated (18) . In the present study, AZD1480 prevented angiogenesis (Fig. 2B, 2C ), confirming those results.
Next, transgenic mice expressing the delE748-A752 mutant of mouse Egfr were treated with AZD1480. In contrast to the case in vitro (Fig. 1C) , AZD1480 suppressed expression of pSTAT3 more than that of pJAK1 and pJAK2 (Fig. 3B) . AZD1480 (30 and 50 mg/kg) by gavage reduced lung tumors in transgenic mice (Fig. 3C) . In this EGFR-addicted lung cancer model, the JAK/STAT3 pathway is not the main route of carcinogenesis or cancer progression; however, interestingly, inhibition of JAK/STAT3 signals leads to significant tumor reduction without suppressing pEGFR (Fig. 3B ). In addition, pSTAT3
was reduced temporally, and apoptosis occurred in the transgenic mice (Fig. 4) . To confirm whether this tumor regression is specific to mice containing the EGFR deletion mutation, L858R transgenic mice (20) were used. AZD1480 (30 and 50 mg/kg) decreased the number of superficial lung tumors along with the reduction in pSTAT3 (Supplemental Fig. 1 ). Thus, AZD1480 was effective for the EGFR-addicted lung cancer model in terms of tumor suppression.
Finally, the effect of AZD1480 on survival was demonstrated (Fig. 5B) . The median survival time in the AZD1480-treated group (217 days) was almost twice that in the control group (106 days).
Transgenic mice treated with AZD1480 survived for a period of time similar to those treated with gefitinib (A) AZD1480 (30 mg/kg/day, n = 13) or vehicle (n = 13) was administered orally from 7 weeks of age.
The AZD1480-treated group displayed a higher weight than the vehicle-treated group (p<0.001 at 9 weeks).
(B) Survival curves. The median survival time in the AZD1480-treated group (217 days) was significantly greater than that in the control group (106 days) (log-rank test, p<0.0001).
Supplemental Figure 1 . AZD1480 (30 and 50 mg/kg) decreased the number of superficial lung tumors and reduced pSTAT3 expression in L858R-transgenic mice.
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